Last reviewed · How we verify
ARM A: Active Comparator Drug
This drug works by inhibiting the BCL-2 protein, preventing cancer cell survival.
This drug works by inhibiting the BCL-2 protein, preventing cancer cell survival. Used for Relapsed or refractory acute myeloid leukemia (AML), Relapsed or refractory acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | ARM A: Active Comparator Drug |
|---|---|
| Sponsor | Grupo Argentino de Tratamiento de la Leucemia Aguda |
| Drug class | BCL-2 inhibitor |
| Target | BCL-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BCL-2 is a key protein that regulates cell death. By inhibiting BCL-2, the drug allows cancer cells to undergo apoptosis, or programmed cell death. This mechanism is particularly effective in treating certain types of leukemia.
Approved indications
- Relapsed or refractory acute myeloid leukemia (AML)
- Relapsed or refractory acute lymphoblastic leukemia (ALL)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics (NA)
- Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine (PHASE4)
- Life Skills-Based Intervention on Substance Use Intention in Adolescents in Social Care Institutions (NA)
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (PHASE3)
- PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (PHASE2, PHASE3)
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: